+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Immunodeficiency Virus (HIV) Point of Care (POC) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • PDF Icon

    Report

  • 95 Pages
  • August 2022
  • Region: Global
  • GlobalData
  • ID: 5656161
The publisher's Medical Devices sector report, 'HIV Point of care (POC) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the HIV Point of care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care.

Scope

  • Extensive coverage of the HIV Point of care (POC) Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of HIV Point of care (POC) Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of HIV Point of care (POC) Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 HIV Point of care (POC) Tests Overview
3 Products under Development
3.1 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
3.2 HIV Point of care (POC) Tests - Pipeline Products by Territory
3.3 HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path
3.4 HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date
3.5 HIV Point of care (POC) Tests - Ongoing Clinical Trials
4 HIV Point of care (POC) Tests - Pipeline Products under Development by Companies
4.1 HIV Point of care (POC) Tests Companies - Pipeline Products by Stage of Development
4.2 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
5 HIV Point of care (POC) Tests Companies and Product Overview
6 Appendix
6.1 Methodology
6.2 About the Publisher
6.3 Contact the Publisher
6.4 Disclaimer
List of Tables
  • HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
  • HIV Point of care (POC) Tests - Pipeline Products by Territory
  • HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path
  • HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date
  • HIV Point of care (POC) Tests - Ongoing Clinical Trials
  • HIV Point of care (POC) Tests Companies - Pipeline Products by Stage of Development
  • HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
  • Glossary
List of Figures
  • HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
  • HIV Point of care (POC) Tests - Pipeline Products by Territory
  • HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path
  • HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date
  • HIV Point of care (POC) Tests - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Rapid Diagnostics GmbH
  • Access Bio Inc
  • Aldatu Biosciences Inc
  • Altratech Ltd
  • Atomo Diagnostics Ltd
  • BBB Technologies Inc
  • Beijing Wantai Biological Pharmacy Enterprise Co Ltd
  • Binx Health Inc
  • Bio-AMD Inc
  • Biocartis Group NV
  • BioHelix Corp
  • Bluejay Diagnostics Inc
  • Calypte Biomedical Corporation
  • Centre International de Reference Chantal Biya
  • Cepheid Inc
  • ChipCare Corp
  • CrossLife Technologies Inc
  • Daktari Diagnostics, Inc.
  • Diagnostics For All Inc
  • Diagnostics for the Real World (Europe) Ltd
  • Endeavor Sciences Inc
  • Epinex Diagnostics Inc
  • ERBA Molecular Ltd
  • Fluxergy LLC
  • GAIA Medical Institute LLC
  • genedrive plc
  • Group K Diagnostics
  • Guangzhou Wondfo Biotech Co Ltd
  • HeatFlow Technologies Inc
  • Identifysensors LLC
  • Imperial College London
  • Integrated Diagnostics Inc (Inactive)
  • Jan Biotech Inc
  • Jinvator Bio Med GmbH
  • Johns Hopkins University
  • Maxim Biomedical Inc
  • MedMira Inc
  • Micronics Inc
  • Molbio Diagnostics Pvt Ltd
  • MyMD Pharmaceuticals, Inc
  • Nanobiosym Inc
  • Newmark Diagnostics LLC
  • Northwestern University
  • Osel Inc
  • Prenetics Ltd
  • QuantuMDx Group Ltd
  • Quidel Corp
  • Radisens Diagnostics Ltd
  • Rheonix Inc
  • Roche Diagnostics International Ltd
  • Sedia Biosciences Corp
  • Senzo Inc
  • TheoremDx Inc
  • Trinity Biotech Plc
  • University of Connecticut
  • University of Minnesota
  • UrSure Inc
  • Ustar Biotechnologies (Hangzhou) Ltd.
  • Wave 80 Biosciences Inc
  • Yaathum Biotech Pvt Ltd